Multiple patient, disease, and treatment-related determinants, such as age, adherence, and comorbidities, significantly influence Time in Therapeutic Range during warfarin therapy.
Maintaining optimal Time in Therapeutic Range (TTR) during warfarin therapy requires addressing multiple clinical determinants through multidisciplinary management, patient education, and regular monitoring.
Effective control of anticoagulation therapy is crucial to minimize the risk of thromboembolic events and bleeding complication. For the prevention and treatment of thromboembolic disorders, warfarin is still frequently recommended orally, especially in patients with atrial fibrillation and mechanical heart valve replacement. However, keeping the International Normalized Ratio (INR) within the therapeutic range is crucial to the clinical efficacy of warfarin therapy. Time in Therapeutic Range (TTR), which represents the proportion of time that INR readings stay within the therapeutic range, is a commonly used indicator of anticoagulation quality. A higher risk of bleeding and thromboembolic consequences is linked to suboptimal TTR. TTR can be greatly impacted by a number of factors, including age, medication adherence, dietary practices, the frequency of INR testing, and drug interactions. In addition to highlighting tactics that could enhance anticoagulation control, this narrative review summarizes the body of research on the variables influencing TTR in patients on warfarin medication.
T et al. (Thu,) conducted a review in Thromboembolic disorders requiring anticoagulation. Warfarin was evaluated on Time in Therapeutic Range (TTR). Multiple patient, disease, and treatment-related determinants, such as age, adherence, and comorbidities, significantly influence Time in Therapeutic Range during warfarin therapy.